$44.97
8.27% today
NYSE, Sep 03, 06:50 pm CET

Hims & Hers Health Inc. Stock price

$41.53
-21.82 34.44% 1M
+0.85 2.09% 6M
+17.35 71.75% YTD
+26.80 181.94% 1Y
+35.44 581.94% 3Y
+30.82 287.77% 5Y
+31.73 323.78% 10Y
+31.73 323.78% 20Y
NYSE, Closing price Tue, Sep 02 2025
-0.82 1.94%

Key metrics

Basic
Market capitalization
$9.4b
Enterprise Value
$9.2b
Net debt
positive
Cash
$1.1b
Shares outstanding
225.8m
Valuation (TTM | estimate)
P/E
55.4 | 69.2
P/S
4.7 | 3.9
EV/Sales
4.6 | 3.9
EV/FCF
77.1
P/B
16.7
Financial Health
Equity Ratio
67.4%
Return on Equity
26.4%
ROCE
8.5%
ROIC
36.3%
Debt/Equity
1.7
Financials (TTM | estimate)
Revenue
$2.0b | $2.4b
EBITDA
$166.1m | $328.8m
EBIT
$136.9m | $176.6m
Net Income
$193.6m | $135.4m
Free Cash Flow
$119.5m
Growth (TTM | estimate)
Revenue
88.7% | 61.8%
EBITDA
526.4% | 286.4%
EBIT
821.9% | 159.7%
Net Income
969.6% | 7.4%
Free Cash Flow
33.5%
Margin (TTM | estimate)
Gross
76.2%
EBITDA
8.3% | 13.8%
EBIT
6.8%
Net
9.6% | 5.7%
Free Cash Flow
5.9%
More
EPS
$0.8
FCF per Share
$0.5
Short interest
38.5%
Employees
2k
Rev per Employee
$900.0k
Show more

Is Hims & Hers Health Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Hims & Hers Health Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

20 Analysts have issued a Hims & Hers Health Inc. forecast:

9x Buy
45%
9x Hold
45%
2x Sell
10%

Analyst Opinions

20 Analysts have issued a Hims & Hers Health Inc. forecast:

Buy
45%
Hold
45%
Sell
10%

Financial data from Hims & Hers Health Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
2,014 2,014
89% 89%
100%
- Direct Costs 479 479
152% 152%
24%
1,534 1,534
75% 75%
76%
- Selling and Administrative Expenses 1,397 1,397
62% 62%
69%
- Research and Development Expense - -
-
-
166 166
526% 526%
8%
- Depreciation and Amortization 29 29
150% 150%
1%
EBIT (Operating Income) EBIT 137 137
822% 822%
7%
Net Profit 194 194
970% 970%
10%

In millions USD.

Don't miss a Thing! We will send you all news about Hims & Hers Health Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Hims & Hers Health Inc. Stock News

Positive
Seeking Alpha
3 days ago
Hims & Hers is fundamentally undervalued, trading at a forecast P/S ratio of 3.5 despite strong 88% YoY growth and European expansion. Low valuation and scaling by ZAVA lead to a buy rating. Short interest remains high, but a squeeze is unlikely; technicals show strong support at $41, signaling a favorable buy zone.
Positive
Seeking Alpha
5 days ago
Hims & Hers is evolving into a robust health platform, showing strong subscriber growth, rising ARPU, and expanding into weight loss, hormone health, labs, and international markets. Q2 results confirm rapid scaling, with 73% YoY revenue growth, high retention, SaaS-like payback, and reaffirmed guidance despite headline noise and regulatory shifts. The weight loss strategy is diversified beyond...
Neutral
GlobeNewsWire
7 days ago
The suit claims Hims misled investors by overstating its partnership with Novo Nordisk and access to Wegovy, causing stock losses when the truth emerged.
More Hims & Hers Health Inc. News

Company Profile

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Head office United States
CEO Andrew Dudum
Employees 1,637
Founded 2017
Website www.forhims.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today